Companies must cease manufacturing and distributing unapproved suppository drug products containing trimethobenzamide hydrochloride, used to treat nausea and vomiting, because such products "lack substantial evidence of effectiveness," FDA says in a Federal Register notice. Suppositories containing trimethobenzamide hydrochloride have included Tigan, Tebamide, T-Gen, Trimazide, and Trimethobenz, the agency notes. Firms must stop shipping them in interstate commerce by May 9, and obtain a new drug application to resume marketing, FDA adds in an April 6 press release. The notice also announces the withdrawal of King's NDA for Tigan suppositories...
You may also be interested in...
Pink Sheet reporters and editor discuss President-Elect Joe Biden’s decision to name the CDER director as acting FDA commissioner and other staffing changes, as well as changes to industry trade groups’ political donations.
Delfi Diagnostics will use the new funds to expand its team of cancer researchers and machine-learning experts to validate its novel approach for early cancer detection through multiple prospective clinical trials.
US Ninth Circuit affirms a district court’s summary judgment in favor of Target and manufacturer of Up & Up brand biotin supplement it sells. Indian manufacturer targeted in putative class-action in New York prompted FDA’s 2016 creation of import alert category for Ayurvedic supplements.